Nutraceutical prospective: The synergetic mechanism of action of inositols and resveratrol on metabolic syndrome

Abstract It has been known that inositols function as insulin second messengers and mediate different insulin-dependent processes and are a valid natural, non-pharmaceutical alternative to contrast insulin-resistance as well as associated metabolic syndrome in women with Polycystic ovarian disease (PCOS). Several studies also have shown positive effects of resveratrol in reducing glucose and lipid concentrations in patients. Recently, clinical evidence has proven that an D-chiro-inositol/resveratrol combination has a potential role to play in maintaining metabolic and endocrine health, however no large clinical trials have demonstrated the medical effectiveness of the combination, and the combined mode of action remains poorly discussed. Herein, we address the hypothesis of a synergistic mechanism adopted by D-chiro-inositol and resveratrol in reducing insulin resistance and hyperlipidemia and thus showing a greater therapeutic potential compared to treatment with inositol’s alone.

Download Full-text

Effect of Alpha-lipoic Acid Supplementation on Glycemic Control in the Patients with Metabolic Syndrome: A Randomized Clinical Trial

10.21203/rs.3.rs-37045/v1 ◽

2020 ◽

Author(s):

Nafiseh Kaviyani ◽

Seyed Ali Keshavarz ◽

Behnood Abbasi

Keyword(s):

Insulin Resistance ◽

Metabolic Syndrome ◽

Clinical Trial ◽

Glycemic Control ◽

Lipoic Acid ◽

Serum Insulin ◽

Alpha Lipoic Acid ◽

Acid Supplementation ◽

Positive Effects ◽

Significant Difference

Abstract BackgroundMetabolic syndrome is a collection of metabolic disorders. It is an important risk factor for progression towards type 2 diabetes and coronary artery diseases. Alpha-lipoic acid also plays a role as a co-factor for multi-enzyme complexes catalyzing oxidative. Antioxidant properties of alpha-lipoic acid (ALA) are associated with insulin-like effects. The present study examined the effect of alpha-lipoic acid supplementation on glycemic control in the patients with metabolic syndrome.MethodsA total of 46 patients with metabolic syndrome have participated in this double-blind randomized parallel-group clinical trial, 23 patients in one group received 600 mg of alpha-lipoic acid supplement and 23 patients in another group received the placebo for 12 weeks. RCT protocol was registered at ClinicalTrials.gov and it is available using NCT03589690 code. Fasting blood sugar (FBS), Serum insulin, Hemoglobin A1c (HbA1c), insulin resistance, were measured at the beginning and the end of the study. Dietary intake of participants was examined at the beginning of the study and this information was evaluated using Nutritionist 4 (N4) software. Studied information was analyzed by SPSS-24 software.ResultsThere were significant decreases in FBS levels (P = 0.009), serum insulin (P = 0.02), and insulin resistance (P = 0.001) between the two groups. Also, the HbA1c levels (P = 0.16) had no significant difference between the two groups.ConclusionALA is a potent antioxidant that it might be able to improve the blood glucose levels, serum insulin and insulin resistance; thus it will have positive effects on promoting the health levels in the patients with metabolic syndrome.Trial registrationNCT03589690

Download Full-text

Recent advances in managing/understanding the metabolic syndrome

F1000Research ◽

10.12688/f1000research.17122.1 ◽

2019 ◽

Vol 8 ◽

pp. 370 ◽

Cited By ~ 8

Author(s):

Carlos A. Aguilar-Salinas ◽

Tannia Viveros-Ruiz

Keyword(s):

Insulin Resistance ◽

Type 2 Diabetes ◽

Metabolic Syndrome ◽

De Novo ◽

New Drugs ◽

Low Grade ◽

Treatment Targets ◽

Positive Effects ◽

The Metabolic Syndrome

The metabolic syndrome (MetS) concept gathers in a single entity a set of metabolic abnormalities that have in common a close relationship with ectopic deposit of lipids, insulin resistance, and chronic low-grade inflammation. It is a valuable teaching tool to help health professionals to understand and integrate the consequences of lipotoxicity and the adverse metabolic consequences of insulin resistance. Also, it is useful to identify subjects with a high risk for having incident type 2 diabetes. Systems biology studies have gained a prominent role in understanding the interaction between adipose tissue dysfunction, insulin action, and the MetS traits and co-morbidities (that is, non-alcoholic steatohepatitis, or NASH). This approach may allow the identification of new therapeutic targets (that is, de novo lipogenesis inhibitors for NASH). Treatment targets on MetS are the adoption of a healthy lifestyle, weight loss, and the control of the co-morbidities (hyperglycemia, dyslipidemia, arterial hypertension, among others). The long-term goals are the prevention of type 2 diabetes, cardiovascular events, and other MetS-related outcomes. In the last few decades, new drugs derived from the identification of innovative treatment targets have come on the market. These drugs have positive effects on more than one MetS component (that is, hyperglycemia and weight control). New potential treatment targets are under study.

Download Full-text

Therapeutic Potential of Retinoid X Receptor Modulators for the Treatment of the Metabolic Syndrome

PPAR Research ◽

10.1155/2007/94156 ◽

2007 ◽

Vol 2007 ◽

pp. 1-12 ◽

Cited By ~ 36

Author(s):

Jane A. Pinaire ◽

Anne Reifel-Miller

Keyword(s):

Insulin Resistance ◽

Type 2 Diabetes ◽

Metabolic Syndrome ◽

Therapeutic Potential ◽

Treatment Options ◽

Additional Treatment ◽

The Metabolic Syndrome ◽

Prevalence Of Obesity ◽

Receptor Modulators

The increasing prevalence of obesity is a fundamental contributor to the growing prevalence of the metabolic syndrome. Rexinoids, a class of compounds that selectively bind and activate RXR, are being studied as a potential option for the treatment of metabolic syndrome. These compounds have glucose-lowering, insulin-sensitizing, and antiobesity effects in animal models of insulin resistance and type 2 diabetes. However, undesirable side effects such as hypertriglyceridemia and suppression of the thyroid hormone axis also occur. This review examines and compares the effects of four RXR-selective ligands: LGD1069, LG100268, AGN194204, and LG101506, a selective RXR modulator. Similar to selective modulators of other nuclear receptors such as the estrogen receptor (SERMs), LG101506 binding to RXR selectively maintains the desirable characteristic effects of rexinoids while minimizing the undesirable effects. These recent findings suggest that, with continued research efforts, RXR-specific ligands with improved pharmacological profiles may eventually be available as additional treatment options for the current epidemic of obesity, insulin resistance, type 2 diabetes, and all of the associated metabolic sequelae.

Download Full-text

Physiotherapy of cicatricial skin changes in the conditions of metabolic syndrome

Fizioterapevt (Physiotherapist) ◽

10.33920/med-14-2012-02 ◽

2020 ◽

pp. 15-21

Author(s):

K. V. Kazantseva ◽

S. N. Nagornev ◽

V. K. Frolkov

Keyword(s):

Insulin Resistance ◽

Metabolic Syndrome ◽

Lipid Metabolism ◽

Therapeutic Potential ◽

Skin Changes ◽

Fractional Photothermolysis ◽

Combined Application ◽

The Metabolic Syndrome ◽

Carbohydrate And Lipid Metabolism ◽

Lipid Metabolism Disorders

The article analyzes the effectiveness of combined application of fractional photothermolysis and fermencol ultraphonophoresis against the background of metabolic syndrome in patients with cicatricial skin changes. It is shown that the efficiency of combined physiotherapy is reduced if it is performed against the background of metabolic syndrome. It is proved that the leading pathogenetic factors of the metabolic syndrome that reduce the therapeutic potential of physiotherapy procedures are insulin resistance and lipid metabolism disorders. It is found that the use of fractional photothermolysis and fermencol ultraphonophoresis does not affect significantly the main parameters of the metabolic syndrome in patients with or without metabolic syndrome. It is suggested that to increase the effectiveness of physiotherapy in patients with cicatricial skin changes in the presence of disorders of carbohydrate and lipid metabolism, provoked by the development of insulin resistance, additional use of therapeutic factors used to correct metabolic disorders is necessary.

Download Full-text

Metabolicheskiy sindrom kak protrombogennoei provospalitel'noe sostoyanie: vliyanieterapevticheskikh meropriyatiy

Obesity and metabolism ◽

10.14341/2071-8713-4871 ◽

2009 ◽

Vol 6 (4) ◽

pp. 3-8

Author(s):

M A Berkovskaya ◽

S A Butrova

Keyword(s):

Insulin Resistance ◽

Metabolic Syndrome ◽

Therapeutic Strategies ◽

Review Article ◽

Main Role ◽

Positive Effects ◽

Physical Exercises ◽

Improve Insulin Resistance ◽

Anti Inflammatory ◽

Main Effects

The review article highlights the main effects of therapeutic strategies on proinflammatory and procoagulant abnormalities which accompany metabolic syndrome. The main role in correction of these abnormalities belongs to dietotherapy and physical exercises. Besides, sometimes it is appropriate to use drugs which improve insulin resistance - metformin and thiazolidinediones - as they display many other positive effects, such as anti-inflammatory and anticoagulant actions.

Download Full-text

Abstract 286: Phytochemical Treatment of Insulin Resistance in Metabolic Syndrome Patients

Arteriosclerosis Thrombosis and Vascular Biology ◽

10.1161/atvb.32.suppl_1.a286 ◽

2012 ◽

Vol 32 (suppl_1) ◽

Author(s):

Günter Siegel ◽

Otto Knes ◽

Sören Just ◽

Karl Winkler ◽

Eugeny Ermilov

Keyword(s):

Insulin Resistance ◽

Metabolic Syndrome ◽

Point Of Care ◽

Second Messengers ◽

Mechanistic Explanation ◽

Diabetic Patients ◽

Beneficial Effects ◽

Cytokine Pattern ◽

Hs Crp ◽

Tolerable Level

Background: Since HOMA-IR predicts coronary artery calcification incidence and progression, but not independently of metabolic syndrome (MS), we sought to determine whether insulin resistance (IR) could be lowered by a phytochemical approach. In a 2-month clinical pilot study with Ginkgo biloba (EGb 761, 2 × 120 mg/d) on 11 MS patients, a novel biomarker spectrum embracing parameters of plaque formation, stability and progression, oxidative stress, inflammation, lipid composition and second messengers, made point-of-care theranostics feasible. Methods: Laser ellipsometry, photometric methods, ELISAs and EIAs were applied. Results: Nanoplaque formation was reduced by 14.3% (p < 0.01), nanoplaque size by 23.4% (p < 0.0004), oxLDL/LDL 21.0% (p < 0.002), 8- iso -PGF 2α 39.8% (p < 0.003), MPO 29.6% (p < 0.01), IL-6 12.9% (p < 0.04), hs-CRP 39.3% (p < 0.005), Lp(a) 26.3% (p < 0.001), MMP-9 32.9% (p < 0.04), whereas SOD was augmented 17.7% (p < 0.01), GPx 11.6% (p < 0.001), cAMP 43.5% (p < 0.001), and cGMP 32.9% (p < 0.001). Since none of the patients had a diabetes, we evaluated IR. Fasting morning glucose was reduced by 4.0% from 94.4 to 90.2 mg/dL (p < 0.03), insulin 8.6% from 12.7 to 11.5 mU/L (p < 0.04), and HOMA-IR 12.3% from 3.07 to 2.64 mU/L×mg/dL (p < 0.02). Because ginkgo is not an antidiabeticum, we looked out for a mechanistic explanation. Insulin (1), glucose (2) and HOMA-IR (3) were correlated to IL-6 (4), hs-CRP (5), TNFα (6) and TGFβ 1 (7), which changes in cytokine pattern could unravel lowering of the former quantities: 1 vs 4 (r = 0.73, p < 0.06); 2 vs 4 (r = 0.80, p < 0.03); 3 vs 4 (r = 0.71, p < 0.07); 1 vs 5 (r = 0.64, p < 0.03); 2 vs 5 (r = 0.75, p < 0.02); 3 vs 5 (r = 0.68, p < 0.14); 1 vs 6 (r = -0.68, p < 0.05); 2 vs 6 (r = -0.73, p < 0.04); 3 vs 6 (r = -0.67, p < 0.05); 1 vs 7 (r = -0.75, p < 0.09); 2 vs 7 (r = -0.70, p < 0.02) and 3 vs 7 (r = -0.89, p < 0.01). Conclusion: Ginkgo had beneficial effects on a multitude of arteriosclerotic and diabetic biomarkers. IR was diminished by 12.3% to an HOMA-IR markedly below 3 on average, a clinically tolerable level. Further, this decrease can explain the reduction in Ca 2+ -dependent nanoplaque formation and size. Thus, ginkgo may be used as complementary drug in the treatment of MS, arteriosclerotic and diabetic patients.

Download Full-text